Aron-Wisnewsky J - Search Results

1

Gut microbiota: a promising target against cardiometabolic diseases.

Warmbrunn MV, Herrema H, Aron-Wisnewsky J, Soeters MR, Van Raalte DH, Nieuwdorp M. Warmbrunn MV, et al. Expert Rev Endocrinol Metab. 2020 Jan;15(1):13-27. doi: 10.1080/17446651.2020.1720511. Expert Rev Endocrinol Metab. 2020. PMID: 32066294 Review.

2

The importance of the gut microbiota after bariatric surgery.

Aron-Wisnewsky J, Doré J, Clement K. Aron-Wisnewsky J, et al. Nat Rev Gastroenterol Hepatol. 2012 Oct;9(10):590-8. doi: 10.1038/nrgastro.2012.161. Epub 2012 Aug 28. Nat Rev Gastroenterol Hepatol. 2012. PMID: 22926153 Review.

3

The gut microbiome, diet, and links to cardiometabolic and chronic disorders.

Aron-Wisnewsky J, Clément K. Aron-Wisnewsky J, et al. Nat Rev Nephrol. 2016 Mar;12(3):169-81. doi: 10.1038/nrneph.2015.191. Epub 2015 Nov 30. Nat Rev Nephrol. 2016. PMID: 26616538 Review.

4

Impact of bariatric surgery on type 2 diabetes: contribution of inflammation and gut microbiome?

Debédat J, Amouyal C, Aron-Wisnewsky J, Clément K. Debédat J, et al. Semin Immunopathol. 2019 Jul;41(4):461-475. doi: 10.1007/s00281-019-00738-3. Epub 2019 Apr 25. Semin Immunopathol. 2019. PMID: 31025085 Free article. Review.

5

Gut Microbiota Dysbiosis in Human Obesity: Impact of Bariatric Surgery.

Debédat J, Clément K, Aron-Wisnewsky J. Debédat J, et al. Curr Obes Rep. 2019 Sep;8(3):229-242. doi: 10.1007/s13679-019-00351-3. Curr Obes Rep. 2019. PMID: 31197613 Free article. Review.

6

Fecal Microbiota Transplantation: a Future Therapeutic Option for Obesity/Diabetes?

Aron-Wisnewsky J, Clément K, Nieuwdorp M. Aron-Wisnewsky J, et al. Curr Diab Rep. 2019 Jun 27;19(8):51. doi: 10.1007/s11892-019-1180-z. Curr Diab Rep. 2019. PMID: 31250122 Free article. Review.

7

Gut microbiota of obese subjects with Prader-Willi syndrome is linked to metabolic health.

Olsson LM, Poitou C, Tremaroli V, Coupaye M, Aron-Wisnewsky J, Bäckhed F, Clément K, Caesar R. Olsson LM, et al. Gut. 2020 Jul;69(7):1229-1238. doi: 10.1136/gutjnl-2019-319322. Epub 2019 Oct 14. Gut. 2020. PMID: 31611297 Free PMC article.

8

Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?

Aron-Wisnewsky J, Warmbrunn MV, Nieuwdorp M, Clément K. Aron-Wisnewsky J, et al. Gastroenterology. 2020 May;158(7):1881-1898. doi: 10.1053/j.gastro.2020.01.049. Epub 2020 Feb 8. Gastroenterology. 2020. PMID: 32044317 Review.

9

Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders.

Aron-Wisnewsky J, Vigliotti C, Witjes J, Le P, Holleboom AG, Verheij J, Nieuwdorp M, Clément K. Aron-Wisnewsky J, et al. Nat Rev Gastroenterol Hepatol. 2020 May;17(5):279-297. doi: 10.1038/s41575-020-0269-9. Epub 2020 Mar 9. Nat Rev Gastroenterol Hepatol. 2020. PMID: 32152478 Review.

10

Statin therapy is associated with lower prevalence of gut microbiota dysbiosis.

Vieira-Silva S, Falony G, Belda E, Nielsen T, Aron-Wisnewsky J, Chakaroun R, Forslund SK, Assmann K, Valles-Colomer M, Nguyen TTD, Proost S, Prifti E, Tremaroli V, Pons N, Le Chatelier E, Andreelli F, Bastard JP, Coelho LP, Galleron N, Hansen TH, Hulot JS, Lewinter C, Pedersen HK, Quinquis B, Rouault C, Roume H, Salem JE, Søndertoft NB, Touch S; MetaCardis Consortium; Dumas ME, Ehrlich SD, Galan P, Gøtze JP, Hansen T, Holst JJ, Køber L, Letunic I, Nielsen J, Oppert JM, Stumvoll M, Vestergaard H, Zucker JD, Bork P, Pedersen O, Bäckhed F, Clément K, Raes J. Vieira-Silva S, et al. Nature. 2020 May;581(7808):310-315. doi: 10.1038/s41586-020-2269-x. Epub 2020 May 6. Nature. 2020. PMID: 32433607

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

115 results

Search Page